Early research shows a one-time gene therapy has potential for addressing both the liver and lung disease that patients with ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...
Lancashire Evening Post on MSN3d
Doctors thought I had a tropical virus after I fell in Thailand, but it turned out to be a brain tumourA Leyland man was initially told he had contracted a tropical virus while travelling in Thailand, but it turned out to be a ...
Even modern cancer treatments appear risky for the heart, especially if the radiation dose to the LAD is high.
Dealbreaker on MSN3d
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough MarketA Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...
The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...
Beam Therapeutics announced positive initial data for BEAM-302 in the Phase I/II trial in Alpha-1 Antitrypsin Deficiency (AATD).
BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.
The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...
While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...
The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback